Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

Cobenfy In Alzheimer’s Psychosis Among Next Readouts

BMS shares fell 5.8% on the company's disclosure of plans to review in-progress trials (Shutterstock)

More from Earnings

More from Business